Bayer, Sysmex Inostics to Develop BEAMing CDx Tests for New Cancer Therapies | GenomeWeb

When Japan's Sysmex disclosed two weeks ago that it had acquired molecular diagnostics services firm Inostics and flow cytometry specialist Partec, it noted that the purchases were designed to aid its foray into personalized medicine and companion diagnostics.

The company wasted no time in pursuing these markets, as this week Sysmex Inostics, the new MDx subsidiary of Sysmex, disclosed that it has signed a collaboration deal with Bayer Healthcare to develop blood-based companion diagnostics for targeted anti-cancer therapies being developed by Bayer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.